Skip to main content
Top
Published in: Clinical Pharmacokinetics 4/2008

01-04-2008 | Review Article

Facilitation of Drug Evaluation in Children by Population Methods and Modelling

Authors: Dr Michel Tod, Vincent Jullien, Gérard Pons

Published in: Clinical Pharmacokinetics | Issue 4/2008

Login to get access

Abstract

The pharmacokinetics and pharmacodynamics of drugs are different in adult and paediatric populations, the latter being particularly heterogeneous. These differences in pharmacokinetics and pharmacodynamics justify specific studies but raise a number of ethical and practical issues. The main practical difficulties to circumvent while performing clinical studies in children are the invasiveness of the procedures and the obstacles to patient recruitment. The invasiveness related to pain/anxiety and blood loss precludes the performance of classical pharmacokinetic studies in children in many instances, particularly in neonates and infants. Population approaches, which rely on pharmacokinetic-pharmacodynamic modelling, are particularly appealing in paediatric populations because these models can cope with sparse data. The relevance of population approaches to investigation of the dose-concentration-effect relationships and to qualitative/quantitative assessment of factors that may explain interindividual variability has already been emphasized.
The aims of this review are to summarize the currently available literature on population pharmacokineticpharmacodynamic studies in children and to discuss a number of recent methodological developments that may facilitate the evaluation of drugs in this population by alleviating invasiveness and, subsequently, facilitating recruitment of patients. The present survey confirms that population approaches in paediatrics have already reached a large audience and that they are mostly used for analysis of sparse data. However, pharmacokineticpharmacodynamic studies in children are still scarce. New classes of models may extend the scope of the use of population models in paediatrics. Kinetic-pharmacodynamic models, where use of the term ‘kinetic’ rather than ‘pharmacokinetic’ emphasizes the absence of pharmacokinetic data, are indirect models where the (unobserved) drug kinetics are described by a single compartment involving a single rate constant. These models, which alleviate the need for blood samples used for the measurement of drug concentration, may be very useful in paediatric studies. Physiological and physiopathological models also have potential applications but require further development. Because the number of measurements in a single individual needs to be limited in children, it is crucial to optimize the design of the experiment in order to avoid inaccurate and unreliable results. In this review, formal optimization and simulation to evaluate a design are presented, and specific problems raised by the application of these techniques in paediatrics are addressed. Finally, the related technique of clinical trial simulation and its applications are presented and discussed.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference American Academy of Pediatrics Committee on Drugs. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1995; 95: 286–94 American Academy of Pediatrics Committee on Drugs. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1995; 95: 286–94
4.
go back to reference Jong GW, Vuto AG, de Hoog M, et al. Unapproved and off-label use of drugs in a children’s hospital [letter]. N Engl J Med 2000; 343: 1125PubMedCrossRef Jong GW, Vuto AG, de Hoog M, et al. Unapproved and off-label use of drugs in a children’s hospital [letter]. N Engl J Med 2000; 343: 1125PubMedCrossRef
5.
go back to reference Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 2000; 320: 79–82PubMedCrossRef Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 2000; 320: 79–82PubMedCrossRef
6.
go back to reference Treluyer JM, Berger JF, Leclerc F, et al. Use of off-label and unlicensed drugs in neonatal and paediatric intensive care in France [abstract no. 46A]. Pediatric Academic Societies Annual Meeting; 1999 May 1–4; San Francisco (CA) Treluyer JM, Berger JF, Leclerc F, et al. Use of off-label and unlicensed drugs in neonatal and paediatric intensive care in France [abstract no. 46A]. Pediatric Academic Societies Annual Meeting; 1999 May 1–4; San Francisco (CA)
7.
go back to reference Bücheier R, Schwab M, Mörike K, et al. Offlabel prescribing to children in primary care in Germany: retrospective cohort study. BMJ 2002; 324: 1311–2CrossRef Bücheier R, Schwab M, Mörike K, et al. Offlabel prescribing to children in primary care in Germany: retrospective cohort study. BMJ 2002; 324: 1311–2CrossRef
8.
go back to reference Schirm E, Tobi H, de Jong-van den Berg LT. Unlicensed and off label drug use by children in the community: cross sectional study. BMJ 2002; 324: 1312–3PubMedCrossRef Schirm E, Tobi H, de Jong-van den Berg LT. Unlicensed and off label drug use by children in the community: cross sectional study. BMJ 2002; 324: 1312–3PubMedCrossRef
9.
go back to reference Jong GW, Eland IA, Sturkenboom MCJM, et al. Unlicensed and off-label prescription of drugs to children: population based cohort study. BMJ 2002; 324: 1313–4CrossRef Jong GW, Eland IA, Sturkenboom MCJM, et al. Unlicensed and off-label prescription of drugs to children: population based cohort study. BMJ 2002; 324: 1313–4CrossRef
10.
go back to reference Chalumeau M, Treluyer JM, Salenave B, et al. Off label and unlicensed drug use among office-based paediatricians. Arch Dis Child 2000; 82: 502–5CrossRef Chalumeau M, Treluyer JM, Salenave B, et al. Off label and unlicensed drug use among office-based paediatricians. Arch Dis Child 2000; 82: 502–5CrossRef
11.
go back to reference O’Donnell CPF, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 2002; 110: e52PubMedCrossRef O’Donnell CPF, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 2002; 110: e52PubMedCrossRef
12.
go back to reference Nahata MC. Lack of pediatrie drug formulations. Pediatrics 1999; 104 Suppl.: 607–9PubMed Nahata MC. Lack of pediatrie drug formulations. Pediatrics 1999; 104 Suppl.: 607–9PubMed
13.
go back to reference Kearns GL, Abdel-Rahman S, Alander SW, et al. Developmental pharmacologydrug disposition, action, and therapy in infants and children. N Eng J Med 2003; 349: 1157–67CrossRef Kearns GL, Abdel-Rahman S, Alander SW, et al. Developmental pharmacologydrug disposition, action, and therapy in infants and children. N Eng J Med 2003; 349: 1157–67CrossRef
15.
go back to reference Gao Y, Pons G, Rey E, et al. Could saliva stand for plasma in theophylline monitoring in asthmatic children? Still a controversial problem. Fundam Clin Pharmacol 1992; 6(4–5): 191–6PubMedCrossRef Gao Y, Pons G, Rey E, et al. Could saliva stand for plasma in theophylline monitoring in asthmatic children? Still a controversial problem. Fundam Clin Pharmacol 1992; 6(4–5): 191–6PubMedCrossRef
16.
go back to reference Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr 2006; 165(11): 741–6PubMedCrossRef Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr 2006; 165(11): 741–6PubMedCrossRef
17.
go back to reference Meibohm B, Läer S, Panetta JC, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005; 7(2): E475–87PubMedCrossRef Meibohm B, Läer S, Panetta JC, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005; 7(2): E475–87PubMedCrossRef
18.
go back to reference Vozeh S, Steimer JL, Rowland M, et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 1996; 30(2): 81–93PubMedCrossRef Vozeh S, Steimer JL, Rowland M, et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 1996; 30(2): 81–93PubMedCrossRef
19.
go back to reference Samara E, Granneman R. Role of population pharmacokinetics in drug development: a pharmaceutical industry perspective. Clin Pharmacokinet 1997; 32(4): 294–312PubMedCrossRef Samara E, Granneman R. Role of population pharmacokinetics in drug development: a pharmaceutical industry perspective. Clin Pharmacokinet 1997; 32(4): 294–312PubMedCrossRef
20.
go back to reference Jackson KA, Rosenbaum SE. The application of population pharmacokinetics to the drug development process. Drug Dev Ind Pharm 1998; 24(12): 1155–62PubMedCrossRef Jackson KA, Rosenbaum SE. The application of population pharmacokinetics to the drug development process. Drug Dev Ind Pharm 1998; 24(12): 1155–62PubMedCrossRef
21.
go back to reference Sun H, Fadiran EO, Jones CD, et al. Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinet 1999; 37(1): 41–58PubMedCrossRef Sun H, Fadiran EO, Jones CD, et al. Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinet 1999; 37(1): 41–58PubMedCrossRef
22.
go back to reference Sheiner L, Wakefield J. Population modelling in drug development. Stat Methods Med Res 1999; 8(3): 183–93PubMedCrossRef Sheiner L, Wakefield J. Population modelling in drug development. Stat Methods Med Res 1999; 8(3): 183–93PubMedCrossRef
24.
go back to reference Sheiner LB, Beal SL, Sambol NC. Study designs for dose-ranging. Clin Pharmacol Ther 1989; 46(1): 63–77PubMedCrossRef Sheiner LB, Beal SL, Sambol NC. Study designs for dose-ranging. Clin Pharmacol Ther 1989; 46(1): 63–77PubMedCrossRef
25.
go back to reference Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46(3): 221–34PubMedCrossRef Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46(3): 221–34PubMedCrossRef
30.
go back to reference Läer S, Elshoff JP, Meibohm B, et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 2005; 46(7): 1322–30PubMedCrossRef Läer S, Elshoff JP, Meibohm B, et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 2005; 46(7): 1322–30PubMedCrossRef
31.
go back to reference Uehlinger DE, Ding RW, Schärer K. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76–89PubMedCrossRef Uehlinger DE, Ding RW, Schärer K. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76–89PubMedCrossRef
32.
go back to reference Port RE, Ding RW, Fies T, et al. Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia. Br J Clin Pharmacol 1998; 46(5): 461–6PubMedCrossRef Port RE, Ding RW, Fies T, et al. Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia. Br J Clin Pharmacol 1998; 46(5): 461–6PubMedCrossRef
33.
go back to reference Jacqmin P, Snoeck E, van Schaick EA, et al. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn 2007; 34(1): 57–85PubMedCrossRef Jacqmin P, Snoeck E, van Schaick EA, et al. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn 2007; 34(1): 57–85PubMedCrossRef
34.
go back to reference Audren F, Tod M, Massin P, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004; 45(10): 3435–41PubMedCrossRef Audren F, Tod M, Massin P, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004; 45(10): 3435–41PubMedCrossRef
35.
go back to reference Pillai G, Gieschke R, Goggin T, et al. A semimechanistic and mechanistic population PK/PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol 2004; 58(6): 618–31PubMedCrossRef Pillai G, Gieschke R, Goggin T, et al. A semimechanistic and mechanistic population PK/PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol 2004; 58(6): 618–31PubMedCrossRef
36.
go back to reference Tod M, Farcy-Afif M, Stocco J, et al. Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Clin Pharmacokinet 2005; 44(4): 417–28PubMedCrossRef Tod M, Farcy-Afif M, Stocco J, et al. Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Clin Pharmacokinet 2005; 44(4): 417–28PubMedCrossRef
37.
go back to reference Gruwez B, Dauphin A, Tod M. A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol. J Pharmacokinet Pharmacodyn 2005; 32(5–6): 663–83PubMedCrossRef Gruwez B, Dauphin A, Tod M. A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol. J Pharmacokinet Pharmacodyn 2005; 32(5–6): 663–83PubMedCrossRef
38.
go back to reference Gruwez B, Poirier MF, Dauphin A, et al. A kinetic-pharmacodynamic model for clinical trial simulation of antidepressant action: application to clomipraminelithium interaction. Contemp Clin Trials 2007; 28(3): 276–87PubMedCrossRef Gruwez B, Poirier MF, Dauphin A, et al. A kinetic-pharmacodynamic model for clinical trial simulation of antidepressant action: application to clomipraminelithium interaction. Contemp Clin Trials 2007; 28(3): 276–87PubMedCrossRef
39.
go back to reference Hénin E, Zuideveld KP, Dartois C, et al. A KPD model for ordered categorical data: application to toxicity score in colorectal cancer patients treated with capecitabine [abstract no. 929; online]. Annual Meeting of the Population Approach Group in Europe; 2006 Jan 14–16; Bruges. Available from URL: http://www.page-meeting.org/?.abstract=929 [Accessed 2008 Feb 19] Hénin E, Zuideveld KP, Dartois C, et al. A KPD model for ordered categorical data: application to toxicity score in colorectal cancer patients treated with capecitabine [abstract no. 929; online]. Annual Meeting of the Population Approach Group in Europe; 2006 Jan 14–16; Bruges. Available from URL: http://​www.​page-meeting.​org/​?​.​abstract=​929 [Accessed 2008 Feb 19]
40.
go back to reference Grass GM, Sinko PJ. Physiologically-based pharmacokinetic simulation modelling. Adv Drug Deliv Rev 2002; 54(3): 433–51PubMedCrossRef Grass GM, Sinko PJ. Physiologically-based pharmacokinetic simulation modelling. Adv Drug Deliv Rev 2002; 54(3): 433–51PubMedCrossRef
41.
go back to reference Nestorov I. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 2001; 120(1–3): 411–20PubMedCrossRef Nestorov I. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 2001; 120(1–3): 411–20PubMedCrossRef
42.
go back to reference Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003; 33: 469–503PubMed Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003; 33: 469–503PubMed
43.
go back to reference Yang F, Tong X, McCarver DG, et al. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 2006; 33(4): 485–518PubMedCrossRef Yang F, Tong X, McCarver DG, et al. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 2006; 33(4): 485–518PubMedCrossRef
44.
go back to reference Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95(6): 1238–57PubMedCrossRef Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95(6): 1238–57PubMedCrossRef
45.
go back to reference Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005; 94(6): 1259–76PubMedCrossRef Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005; 94(6): 1259–76PubMedCrossRef
46.
go back to reference Nestorov IA, Aarons LJ, Arundel PA, et al. Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 1998; 26(1): 21–46PubMedCrossRef Nestorov IA, Aarons LJ, Arundel PA, et al. Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 1998; 26(1): 21–46PubMedCrossRef
47.
go back to reference Gueorguieva I, Nestorov IA, Rowland M. Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study. J Pharmacokinet Pharmacodyn 2006; 33(1): 1–27PubMedCrossRef Gueorguieva I, Nestorov IA, Rowland M. Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study. J Pharmacokinet Pharmacodyn 2006; 33(1): 1–27PubMedCrossRef
48.
go back to reference Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 2006; 45(10): 1013–34PubMedCrossRef Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 2006; 45(10): 1013–34PubMedCrossRef
49.
go back to reference Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45(9): 931–56PubMedCrossRef Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45(9): 931–56PubMedCrossRef
50.
go back to reference Wodarz D, Nowak MA. Mathematical models of HIV pathogenesis and treatment. Bioessays 2002; 24(12): 1178–87PubMedCrossRef Wodarz D, Nowak MA. Mathematical models of HIV pathogenesis and treatment. Bioessays 2002; 24(12): 1178–87PubMedCrossRef
51.
go back to reference Duval V, Chabaud S, Girard P, et al. Physiologically based model of acute ischemic stroke. J Cereb Blood Flow Metab 2002; 22(8): 1010–8PubMedCrossRef Duval V, Chabaud S, Girard P, et al. Physiologically based model of acute ischemic stroke. J Cereb Blood Flow Metab 2002; 22(8): 1010–8PubMedCrossRef
52.
go back to reference Chabaud S, Girard P, Nony P, et al. Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris. J Pharmacokinet Pharmacodyn 2002; 29(4): 339–63PubMedCrossRef Chabaud S, Girard P, Nony P, et al. Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris. J Pharmacokinet Pharmacodyn 2002; 29(4): 339–63PubMedCrossRef
53.
go back to reference Post TM, Freijer JI, DeJongh J, et al. Disease system analysis: basic disease progression models in degenerative disease. Pharm Res 2005; 22(7): 1038–49PubMedCrossRef Post TM, Freijer JI, DeJongh J, et al. Disease system analysis: basic disease progression models in degenerative disease. Pharm Res 2005; 22(7): 1038–49PubMedCrossRef
54.
go back to reference Holford NH, Chan PL, Nutt JG, et al. Disease progression and pharmacodynamics in Parkinson disease: evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 2006; 33(3): 281–311PubMedCrossRef Holford NH, Chan PL, Nutt JG, et al. Disease progression and pharmacodynamics in Parkinson disease: evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 2006; 33(3): 281–311PubMedCrossRef
55.
go back to reference Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters: III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983; 11(3): 303–19PubMedCrossRef Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters: III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983; 11(3): 303–19PubMedCrossRef
56.
go back to reference Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm 1991; 19(3): 333–53PubMedCrossRef Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm 1991; 19(3): 333–53PubMedCrossRef
57.
go back to reference Al Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm 1990; 18: 347–60PubMedCrossRef Al Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm 1990; 18: 347–60PubMedCrossRef
58.
go back to reference Ette EI, Howie CA, Kelman AW, et al. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies. Pharm Res 1995; 12(5): 729–37PubMedCrossRef Ette EI, Howie CA, Kelman AW, et al. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies. Pharm Res 1995; 12(5): 729–37PubMedCrossRef
59.
go back to reference Aarons L, Balant LP, Mentré F, et al. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol 1996; 49(4): 251–4PubMedCrossRef Aarons L, Balant LP, Mentré F, et al. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol 1996; 49(4): 251–4PubMedCrossRef
60.
go back to reference Mallet A, Mentré F. An approach to the design of experiments for estimating the distribution of parameters in random models. In: Vichinevetsky R, Borne P, Vignes J, editors. 12th IMACS World Congress; 1988 Jul 18–22. Villeneuve d’Ascq: Gerfidn, 1988: 134-7 Mallet A, Mentré F. An approach to the design of experiments for estimating the distribution of parameters in random models. In: Vichinevetsky R, Borne P, Vignes J, editors. 12th IMACS World Congress; 1988 Jul 18–22. Villeneuve d’Ascq: Gerfidn, 1988: 134-7
61.
go back to reference Mentré F, Mallet A, Baccar D. Optimal design in random-effects regression models. Biometrika 1997; 84: 429–42CrossRef Mentré F, Mallet A, Baccar D. Optimal design in random-effects regression models. Biometrika 1997; 84: 429–42CrossRef
62.
go back to reference Merlé Y, Tod M. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design. J Pharmacokinet Biopharm 2001; 4: 365–90 Merlé Y, Tod M. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design. J Pharmacokinet Biopharm 2001; 4: 365–90
63.
go back to reference Retout S, Duffull S, Mentré F. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Methods Programs Biomed 2001; 65(2): 141–51PubMedCrossRef Retout S, Duffull S, Mentré F. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Methods Programs Biomed 2001; 65(2): 141–51PubMedCrossRef
64.
go back to reference Retout S, Mentré F, Bruno R. Fisher information matrix for non-linear mixedeffects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. Stat Med 2002; 21(18): 2623–39PubMedCrossRef Retout S, Mentré F, Bruno R. Fisher information matrix for non-linear mixedeffects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. Stat Med 2002; 21(18): 2623–39PubMedCrossRef
65.
go back to reference Duffull SB, Retout S, Mentré F. The use of simulated annealing for finding optimal population designs. Comput Methods Programs Biomed 2002; 69(1): 25–35PubMedCrossRef Duffull SB, Retout S, Mentré F. The use of simulated annealing for finding optimal population designs. Comput Methods Programs Biomed 2002; 69(1): 25–35PubMedCrossRef
66.
go back to reference Mentré F, Dubruc C, Thenot JP. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. J Pharmacokinet Pharmacodyn 2001; 28(3): 299–319PubMedCrossRef Mentré F, Dubruc C, Thenot JP. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. J Pharmacokinet Pharmacodyn 2001; 28(3): 299–319PubMedCrossRef
67.
go back to reference Duffull SB, Mentré F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharm Res 2001; 18(1): 83–9PubMedCrossRef Duffull SB, Mentré F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharm Res 2001; 18(1): 83–9PubMedCrossRef
68.
go back to reference Retout S, Mentré F. Optimization of individual and population designs using Splus. J Pharmacokinet Pharmacodyn 2003; 30(6): 417–43PubMedCrossRef Retout S, Mentré F. Optimization of individual and population designs using Splus. J Pharmacokinet Pharmacodyn 2003; 30(6): 417–43PubMedCrossRef
69.
go back to reference Duffull S, Waterhouse T, Eccleston J. Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2005; 32(3–4): 441–57PubMedCrossRef Duffull S, Waterhouse T, Eccleston J. Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2005; 32(3–4): 441–57PubMedCrossRef
70.
go back to reference Tod M, Mentré F, Merlé Y, et al. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics. J Pharmacokinet Biopharm 1998; 26: 689–716PubMedCrossRef Tod M, Mentré F, Merlé Y, et al. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics. J Pharmacokinet Biopharm 1998; 26: 689–716PubMedCrossRef
71.
go back to reference Dodds MG, Hooker AC, Vicini P. Robust population pharmacokinetic experiment design. J Pharmacokinet Pharmacodyn 2005; 32(1): 33–64PubMedCrossRef Dodds MG, Hooker AC, Vicini P. Robust population pharmacokinetic experiment design. J Pharmacokinet Pharmacodyn 2005; 32(1): 33–64PubMedCrossRef
72.
go back to reference Foracchia M, Hooker A, Vicini P, et al. POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 2004; 74(1): 29–46PubMedCrossRef Foracchia M, Hooker A, Vicini P, et al. POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 2004; 74(1): 29–46PubMedCrossRef
73.
go back to reference Palmer JL, Muller P. Bayesian optimal design in population models for haematologic data. Stat Med 1998; 17(14): 1613–22PubMedCrossRef Palmer JL, Muller P. Bayesian optimal design in population models for haematologic data. Stat Med 1998; 17(14): 1613–22PubMedCrossRef
74.
go back to reference Mentré F, Burtin P, Merlé Y, et al. Sparse-sampling optimal designs in pharmacokinetics and toxicokinetics. Drug Inform J 1995; 29: 997–1019CrossRef Mentré F, Burtin P, Merlé Y, et al. Sparse-sampling optimal designs in pharmacokinetics and toxicokinetics. Drug Inform J 1995; 29: 997–1019CrossRef
75.
go back to reference Hooker A, Vicini P. Simultaneous population optimal design for pharmacokineticpharmacodynamic experiments. AAPS J 2005 Nov 1; 7(4): E759–85PubMedCrossRef Hooker A, Vicini P. Simultaneous population optimal design for pharmacokineticpharmacodynamic experiments. AAPS J 2005 Nov 1; 7(4): E759–85PubMedCrossRef
76.
go back to reference Wang J, Endrenyi L. A computationally efficient approach for the design of population pharmacokinetic studies. J Pharmacokin Biopharm 1992; 20: 279–94CrossRef Wang J, Endrenyi L. A computationally efficient approach for the design of population pharmacokinetic studies. J Pharmacokin Biopharm 1992; 20: 279–94CrossRef
77.
go back to reference Kowalski KG, Hutmacher MM. Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. Stat Med 2001; 20(1): 75–91PubMedCrossRef Kowalski KG, Hutmacher MM. Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. Stat Med 2001; 20(1): 75–91PubMedCrossRef
78.
go back to reference Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003; 33(5): 469–503PubMed Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003; 33(5): 469–503PubMed
79.
go back to reference Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci 2004; 93(10): 2522–34PubMedCrossRef Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci 2004; 93(10): 2522–34PubMedCrossRef
80.
go back to reference West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284(5420): 1677–9PubMedCrossRef West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284(5420): 1677–9PubMedCrossRef
81.
go back to reference West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276(5309): 122–6PubMedCrossRef West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276(5309): 122–6PubMedCrossRef
82.
go back to reference Anderson BJ, Allegaert K, Van den Anker JN, et al. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 2007; 63(1): 75–84PubMedCrossRef Anderson BJ, Allegaert K, Van den Anker JN, et al. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 2007; 63(1): 75–84PubMedCrossRef
83.
go back to reference Tod M, Lokiec F, Bidault R, et al. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother 2001; 45(1): 150–7PubMedCrossRef Tod M, Lokiec F, Bidault R, et al. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother 2001; 45(1): 150–7PubMedCrossRef
84.
go back to reference De Bony F, Tod M, Bidault R, et al. Multiple interactions of Cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother 2002; 46(2): 458–63PubMedCrossRef De Bony F, Tod M, Bidault R, et al. Multiple interactions of Cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother 2002; 46(2): 458–63PubMedCrossRef
85.
go back to reference Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci 2000; 2(1): E3PubMed Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci 2000; 2(1): E3PubMed
86.
go back to reference Hale M, Gillespie WR, Gupta SK, et al. Clinical trials simulation: streamlining your drug development process. Appl Clin Trial 1996; 5: 35–40 Hale M, Gillespie WR, Gupta SK, et al. Clinical trials simulation: streamlining your drug development process. Appl Clin Trial 1996; 5: 35–40
87.
go back to reference Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci 1992; 81(6): 605–10PubMedCrossRef Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci 1992; 81(6): 605–10PubMedCrossRef
88.
go back to reference Holford NH, Kimko HC, Monteleone JP, et al. Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2000; 40: 209–34PubMedCrossRef Holford NH, Kimko HC, Monteleone JP, et al. Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2000; 40: 209–34PubMedCrossRef
89.
go back to reference European Center of Pharmaceutical Medicine/Center for Drug Development Science. Frontiers in Drug Development: Computer Simulation and Modelling; 1996 Oct 18; Basel European Center of Pharmaceutical Medicine/Center for Drug Development Science. Frontiers in Drug Development: Computer Simulation and Modelling; 1996 Oct 18; Basel
90.
go back to reference Center for Drug Development Science. Modeling and Simulation of Clinical Trials in Drug Development and Regulation; 1997 Nov; Reston (VA) Center for Drug Development Science. Modeling and Simulation of Clinical Trials in Drug Development and Regulation; 1997 Nov; Reston (VA)
92.
93.
go back to reference Gieschke R, Reigner BG, Steimer JL. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Int J Clin Pharmacol Ther 1997; 35(10): 469–74PubMed Gieschke R, Reigner BG, Steimer JL. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Int J Clin Pharmacol Ther 1997; 35(10): 469–74PubMed
94.
go back to reference Girard P. Clinical trial simulation: a tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol 2005; 96(3): 228–34PubMedCrossRef Girard P. Clinical trial simulation: a tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol 2005; 96(3): 228–34PubMedCrossRef
95.
go back to reference Girard P, Sheiner LB, Kastrissios H, et al. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm 1996; 24(3): 265–82PubMedCrossRef Girard P, Sheiner LB, Kastrissios H, et al. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm 1996; 24(3): 265–82PubMedCrossRef
96.
go back to reference Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance. Stat Med 1998; 17(20): 2313–33PubMedCrossRef Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance. Stat Med 1998; 17(20): 2313–33PubMedCrossRef
97.
go back to reference Wong D, Modi R, Ramanathan M. Assessment of Markov-dependent stochastic models for drug administration compliance. Clin Pharmacokinet 2003; 42(2): 193–204PubMedCrossRef Wong D, Modi R, Ramanathan M. Assessment of Markov-dependent stochastic models for drug administration compliance. Clin Pharmacokinet 2003; 42(2): 193–204PubMedCrossRef
98.
go back to reference Labbe L, Verotta D. A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients. J Pharmacokinet Pharmacodyn 2006; 33(4): 519–42PubMedCrossRef Labbe L, Verotta D. A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients. J Pharmacokinet Pharmacodyn 2006; 33(4): 519–42PubMedCrossRef
99.
go back to reference Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003; 30(1): 83–103PubMedCrossRef Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003; 30(1): 83–103PubMedCrossRef
100.
go back to reference Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64(6): 672–83PubMedCrossRef Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64(6): 672–83PubMedCrossRef
101.
go back to reference Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996; 60(6): 619–35PubMedCrossRef Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996; 60(6): 619–35PubMedCrossRef
102.
go back to reference Veyrat-Follet C, Bruno R, Olivares R, et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000; 68(6): 677–87PubMedCrossRef Veyrat-Follet C, Bruno R, Olivares R, et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000; 68(6): 677–87PubMedCrossRef
103.
go back to reference Nestorov I, Graham G, Duffull S, et al. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm Res 2001; 18(8): 1210–9PubMedCrossRef Nestorov I, Graham G, Duffull S, et al. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm Res 2001; 18(8): 1210–9PubMedCrossRef
104.
go back to reference Jumbe N, Yao B, Rovetti R, et al. Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia. Oncology (Huntingt) 2002; 16 (10 Suppl.11): 37–44 Jumbe N, Yao B, Rovetti R, et al. Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia. Oncology (Huntingt) 2002; 16 (10 Suppl.11): 37–44
105.
go back to reference Lockwood P, Ewy W, Hermann D, et al. Application of a clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer’s disease. Pharm Res 2006; 23: 2050–9PubMedCrossRef Lockwood P, Ewy W, Hermann D, et al. Application of a clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer’s disease. Pharm Res 2006; 23: 2050–9PubMedCrossRef
106.
go back to reference Kimko HC, Reele SS, Holford NH, et al. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 2000; 68(5): 568–77PubMedCrossRef Kimko HC, Reele SS, Holford NH, et al. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 2000; 68(5): 568–77PubMedCrossRef
107.
go back to reference Krishna R, Krishnaswami S, Kittner B, et al. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. Biopharm Drug Dispos 2004; 25(9): 373–87PubMedCrossRef Krishna R, Krishnaswami S, Kittner B, et al. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. Biopharm Drug Dispos 2004; 25(9): 373–87PubMedCrossRef
108.
go back to reference Yim DS, Zhou H, Buckwalter M, et al. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 2005; 45(3): 246–56PubMedCrossRef Yim DS, Zhou H, Buckwalter M, et al. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 2005; 45(3): 246–56PubMedCrossRef
109.
go back to reference Avramis VI, Spence SA. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK/PD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol 2007; 29(4): 239–47PubMedCrossRef Avramis VI, Spence SA. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK/PD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol 2007; 29(4): 239–47PubMedCrossRef
110.
go back to reference Ramakrishnan R, Migoya E, Knorr B. A population pharmacokinetic model for montelukast disposition in adults and children. Pharm Res 2005; 22(4): 532–40PubMedCrossRef Ramakrishnan R, Migoya E, Knorr B. A population pharmacokinetic model for montelukast disposition in adults and children. Pharm Res 2005; 22(4): 532–40PubMedCrossRef
111.
go back to reference Blumer JL, Reed MD, Kaplan EL, et al. Explaining the poor bacteriologie eradication rate of single-dose ceftriaxone in group A streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling. Pediatrics 2005; 116(4): 927–32PubMedCrossRef Blumer JL, Reed MD, Kaplan EL, et al. Explaining the poor bacteriologie eradication rate of single-dose ceftriaxone in group A streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling. Pediatrics 2005; 116(4): 927–32PubMedCrossRef
Metadata
Title
Facilitation of Drug Evaluation in Children by Population Methods and Modelling
Authors
Dr Michel Tod
Vincent Jullien
Gérard Pons
Publication date
01-04-2008
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 4/2008
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200847040-00002

Other articles of this Issue 4/2008

Clinical Pharmacokinetics 4/2008 Go to the issue